Welcome to our dedicated page for Prenetics SEC filings (Ticker: PRE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Prenetics Global Limited filings document a foreign private issuer that furnishes Form 6-K reports for material corporate updates, financial results and press-release exhibits. The filings cover the company’s IM8 consumer health and longevity business, including product and partnership announcements, operating results, registration-statement incorporation and disclosures tied to its focus on global expansion of the brand.
The filing record also documents capital allocation and governance matters, including Class A Ordinary Share repurchase authorization, executive open-market share purchases, board changes, treasury policy related to digital assets and completed divestiture activity such as the sale of the company’s Insighta equity interest. These disclosures frame Prenetics’ capital structure, liquidity commentary and reported business priorities as a public foreign issuer.
Prenetics Global Ltd director Cheng Yin Pan, through wholly owned entity M13 Capital Management Holdings Limited, exercised vested Restricted Stock Units into ordinary shares. On June 15, 2026, 15,873 RSUs converted into 15,873 Class A Ordinary Shares at a price of $0.0000 per share.
After the transaction, M13 Capital Management Holdings Limited held 59,051 Class A Ordinary Shares indirectly and 6,406 RSUs remained outstanding. This was a compensation-related RSU settlement rather than an open-market purchase or sale.
Prenetics Global Ltd director David Vanderveen exercised equity awards and received additional shares as part of his departure from the board. On June 15, 2026, 6,944 Class A Ordinary Shares were issued and delivered upon settlement of vested Restricted Stock Units granted under the company’s 2022 Share Incentive Plan.
Each RSU represents a right to receive one Class A Ordinary Share, and a derivative entry in the filing shows 8,681 RSUs tied to the same underlying shares. Any remaining unvested RSUs were forfeited in connection with Vanderveen’s termination of service as director. Following these settlements, he directly holds 45,249 Class A Ordinary Shares.
Prenetics Global Ltd director Leogrande Hudson Blake reported an initial holding of 24,004 Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one Class A Ordinary Share at an exercise price of $0.0000 per share. The 24,004 RSUs vested on June 4, 2026 and, subject to continued service, will be settled in shares through 12 equal monthly installments beginning July 4, 2026, with the full balance delivered by June 4, 2027.
Prenetics Global Limited reported strong growth for Q1 2026 while remaining loss-making. Revenue from continuing operations reached $36.0 million, with its IM8 nutrition brand contributing $33.8 million, up 23.1% from Q4 2025 and nearly six times Q1 2025 IM8 revenue.
Gross profit was $23.3 million, but loss from operations was $8.9 million and adjusted EBITDA showed a loss of $5.6 million. The total loss of $23.1 million was driven mainly by non‑cash items: an unrealized fair value loss on digital assets of about $9.8 million and an $8.0 million fair value loss on warrant liabilities.
IM8 momentum has accelerated into Q2 2026, with May monthly revenue of about $16.7 million, implying annualized recurring revenue of roughly $200 million. Management raised full‑year 2026 IM8 revenue guidance to $190–210 million and guided Q2 2026 revenue to $46–48 million, mostly from IM8. Prenetics also completed a full divestiture of digital assets for $41.3 million, held cash of $56.0 million as of March 31, 2026, and executed about $19 million of share repurchases under a $40 million program, while remaining debt‑free.
Prenetics Global Limited reports a board change and highlights rapid growth at its IM8 health brand. Director David Vanderveen resigned effective June 4, 2026, and the company appointed Hudson Leogrande, Founder and CEO of Comfrt, as an independent director. With his appointment, three of Prenetics’ four directors are independent under Nasdaq rules. IM8 has reached $100 million in annualized recurring revenue in 11 months and is projected to reach $250 million to $300 million ARR by the end of 2026. Prenetics recently raised its full-year 2026 IM8 revenue guidance to $190 million to $210 million and plans to apply Comfrt’s TikTok and Meta social commerce playbook to accelerate IM8’s expansion.
Cheng Yin Pan reported acquisition or exercise transactions in this Form 4 filing.
Prenetics Global Ltd director Cheng Yin Pan, through wholly owned entity M13 Capital Management Holdings Ltd, received a grant of 6,406 Restricted Stock Units under the company’s 2022 Share Incentive Plan. Each RSU represents the right to receive one Class A Ordinary Share.
The 6,406 RSUs are scheduled to vest on May 17, 2027, subject to continued service. After this grant, indirect holdings reported for this award total 22,279 RSUs. Vested RSUs are not automatically settled; delivery of Class A Ordinary Shares occurs at Cheng Yin Pan’s election in line with the company’s insider trading policy.
Prenetics Global Ltd director Cheng Yin Pan has amended insider disclosures to detail indirect holdings through M13 Capital Management Holdings Limited, a British Virgin Islands company wholly owned by him. M13 holds 43,178 Class A Ordinary Shares, 48,816 underlying warrant shares and 15,873 restricted stock units.
The warrants were originally issued in connection with Prenetics’ initial business combination completed on May 18, 2022 and, after a 1-for-15 reverse stock split on November 14, 2023, are exercisable for 48,816 Class A shares at an exercise price of $133.65 per 1.29 shares, or an effective $103.60 per share. The 15,873 RSUs vest on May 17, 2026 and each represents the right to receive one Class A share, with settlement timing elected by Cheng Yin Pan under the company’s insider trading policy.
Prenetics Global Ltd reported that Chief Financial Officer Lo Hoi Chun received a grant of 91,629 Restricted Stock Units (RSUs), each representing the right to receive one Class A ordinary share. These RSUs were granted under the company’s 2022 Share Incentive Plan as compensation.
The RSUs vest over time, with 7,635 RSUs vesting on May 19, 2026, 7,635.75 RSUs vesting on the 19th of each subsequent month through March 19, 2027 (total 76,358 shares), and 7,636 RSUs vesting on April 19, 2027. After this award, Lo Hoi Chun is reported as holding 597,930 RSUs.
Vested RSUs are not automatically converted into shares. Instead, settlement and delivery of Class A ordinary shares occur at Lo Hoi Chun’s election, in line with the company’s insider trading policy. This is a non-cash equity compensation grant, not an open-market share purchase or sale.
Prenetics Global Limited, parent of premium health brand IM8, announced a multi-year global partnership with author and podcast host Jay Shetty, who becomes IM8’s Global Ambassador and a shareholder in Prenetics. This expands IM8’s reach beyond sport into Shetty’s large wellness-focused audience.
The announcement comes as IM8 raises its full-year 2026 revenue guidance to $190 million to $210 million after reporting preliminary Q1 2026 IM8 revenue of $33.8 million, nearly six times higher year over year. IM8’s May 2026 monthly revenue is tracking at about $15.5 million, implying roughly $186 million in annualized recurring revenue.
Prenetics Global Limited, parent of premium health brand IM8, has appointed Brian J. Rosin as Chief Financial Officer of IM8. He brings nearly two decades of finance leadership in consumer e-commerce and wellness subscriptions and will report to CEO Danny Yeung.
The company highlights IM8 as one of the fastest-growing consumer health supplement brands, now sold in more than 40 countries and having surpassed $100 million in annualized recurring revenue within 11 months of launch. IM8 is projecting $190 million to $210 million in revenue for full year 2026, only its second year from launch, underscoring management’s expectations for rapid global expansion.
Prenetics Global Limited, parent of premium health brand IM8, has appointed Brian J. Rosin as Chief Financial Officer of IM8. He brings nearly two decades of finance leadership in consumer e-commerce and wellness subscriptions and will report to CEO Danny Yeung.
The company highlights IM8 as one of the fastest-growing consumer health supplement brands, now sold in more than 40 countries and having surpassed $100 million in annualized recurring revenue within 11 months of launch. IM8 is projecting $190 million to $210 million in revenue for full year 2026, only its second year from launch, underscoring management’s expectations for rapid global expansion.